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Abstract The objective of this research study was to assess pharmacological, somatic and/or 
psychological treatments in adults with a diagnosis of major depressive disorder who have not 
responded to at least one course of antidepressant medication. We conducted a systematic 
review to identify systematic scientific reviews and meta-analyses on treatment-resistant 
depression (TRD) published until February 2012. Of the sixty studies selected, sixteen met the 
inclusion criteria and were therefore included in the review. We considered eight main themes, 
including the definition of TRD, long-term results, and different treatment strategies, including 
so-called somatic therapies. Based on the review, the definition of TRD should be standardized 
in order to achieve a shared conceptualization of this disorder. This would allow a better 
understanding among clinicians and researchers in the field, promoting a homogeneous research 
methodology and thus leading to more reliable and comparable results. This essential conceptual 
clarification would also have a positive impact on patients with TRD, their families, and social 
and health systems.
© 2013 Asociación Española de Psicología Conductual. Published by Elsevier España, S.L.  
All rights reserved.
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Resumen El objetivo de esta investigación es analizar la literatura científica sobre los trata-
mientos farmacológicos, somáticos y/o psicológicos en adultos con diagnóstico de un trastorno 
depresivo mayor que no han respondido al menos a un tratamiento con antidepresivos. Se llevó 
a cabo una revisión sistemática sin limitación temporal para identificar las revisiones sistemáti-
cas y meta-análisis publicados hasta febrero de 2012 en DRT. Sesenta estudios fueron seleccio-
nados de entre los cuales quedaron incluidos dieciséis al cumplir con los criterios de inclusión. 
Se sintetizan ocho temas principales entre los que cabe destacar la definición, resultados a 
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Depression is one of the most common mental disorders in 
current Western societies. At present, it continues to grow 
in numbers and is one of the main causes of disability 
around the world, particularly in high-income regions (e.g., 
Davidson, 2010; McKenna, Michaud, Murray, & Marks, 2005; 
World Health Organization [WHO], 2005). To deal with this 
relevant health and social problem, there are several effi-
cient interventions such as use of antidepressant drugs 
(ADs; Geddes et al., 2003; Perestelo-Pérez et al., 2010) and 
psychological treatments, particularly those derived from a 
cognitive-behavioural approach (Aguilera, Garza, & Muñoz, 
2010; Kaltenthaler et al., 2006; Merry, McDowell, Hetrick, 
Bir, & Muller, 2004). 
Despite these efficient treatment tools, up to 50% of in-
dividuals with depression do not show significant clinical 
recovery. Hence, a large proportion of the burden caused 
by depression has been attributed to ‘treatment-resistant 
depression’ (TRD; Álvarez et al., 2008; Eby & Eby, 2010; 
Jenkins & Goldner, 2012). 
TRD is most likely to occur with comorbid physical and 
mental disorders as well as marked and protracted func-
tional impairment. It is highly recurrent, with as many as 
80% of patients who require multiple treatments relapsing 
within a year of remission and a probability of recovery of 
about 40% within 10 years. Thus, TRD is the subject of a 
considerable amount of research aimed at reducing the 
substantial burden and high healthcare costs it originates 
(Fekadu et al., 2009).
As happens with other depressive disorders, there are 
different treatment approaches to TRD. New protocols 
and treatment resources have been developed to treat 
this disorder. A few examples are combination or augmen-
tation strategies (Mahmoud et al., 2007; Shelton, Osun-
tokun, Heinloth, & Corya, 2010; Vigo & Baldessarini, 2009) 
and repetitive transcranial magnetic stimulation (rTMS; 
Padberg & George 2009; Schlaepfer, George, & Mayberg, 
2009). Despite these efforts, the situation remains unclear 
and no specific protocol is recommended to treat TRD 
(National Institute for Health and Clinical Excellence 
[NICE], 2009).
The aim of the present systematic review (SR) was to 
identify published systematic reviews (SRs) and meta-anal-
yses to assess pharmacological, somatic and/or psychologi-
cal treatments in adults with a diagnosis of major depres-
sive disorder who have not responded to at least one course 
of antidepressant medication. We conducted this SR based 
on the recommendations of Fernández-Ríos and Buela-Casal 
(2009) and Perestelo-Pérez (2013).
Method
Search strategy
We systematically reviewed materials published until Sep-
tember 2012, consulting the following databases: Medline, 
Medline In-Process, Old Medline, Embase, Cochrane, Cinahl, 
and PsychInfo. We developed a search strategy for each 
electronic database using the combination of the following 
Medical Subject Heading (MeSH) and free-text terms: phar-
macology, antidepressant, psychology, psychotherapy, psy-
choeducation, combination, depression, depressive disor-
ders, systematic, review, and the names of individual 
antidepressants and individual psychotherapies. An experi-
enced information specialist developed, tested, and re-
fined the search strategies with input from the authors (full 
details are available on request).
To complete the information sources, we scrutinized ref-
erence lists of selected review papers manually for further 
relevant articles and reports. We increased the number of 
articles available by conducting additional searches on the 
Internet and in book chapters and contacting relevant au-
thors in the field.
Inclusion and exclusion criteria
The scientific articles included in the SR were systematic re-
views (SRs) and meta-analyses on TRD assessing the efficacy 
of pharmacological, somatic and/or psychological treat-
ments for TRD with the aim of directly or indirectly improv-
ing patients’ depressive state. No language restrictions were 
applied. Intra-group comparison studies, narrative reviews, 
case studies, and expert consensus studies were excluded.
Studies included were those in which participants were 
adults up to 65 years old with a depressive disorder accord-
ing to the diagnostic criteria of the International Statistical 
Classification of Diseases and Related Health Problems 
(CIE-10; World Health Organization, 1992) or the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV; Ameri-
can Psychiatric Association [APA], 2000); participants had 
to suffer from TRD, understood as depression that had not 
responded to two adequate antidepressant treatments, or 
be recruited according to their scores in a validated ques-
tionnaire measuring depression such as the Montgomery-
Asberg Depression Rating Scale (MADRS, Montgomery & As-
berg, 1979) or the HAMD rating scale (Hamilton, 1960).
Studies excluded were those in which participants had 
any of the following: an episode or disorder attributable to 
largo plazo y diferentes estrategias de tratamiento, incluyendo las llamadas terapias somáticas. 
Actualmente existe una necesidad de estandarizar la definición para la DRT con el fin de homo-
geneizar su conceptualización. Esto permitirá un mayor entendimiento entre los clínicos e in-
vestigadores en el campo, la promoción de una metodología de investigación homogénea y la 
obtención de resultados más fiables y comparables. Esto tendrá también un impacto positivo en 
los pacientes que sufren de DRT, sus familias y los sistemas sociales y de salud.
© 2013 Asociación Española de Psicología Conductual. Publicado por Elsevier España, S.L.  
Todos los derechos reservados.
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the consumption of psychoactive substances or to a medi-
cal illness, a history of episodes of hypomania, mania, or a 
combination of both, a cyclothymic disorder, a new major 
Depressive episode or one superimposed to or better ex-
plained by another mental disorder, any other organic men-
tal disorders, or pregnancy-related depression. Studies in-
volving infant, youth, or geriatric patients were also ex-
cluded.
Study selection process
The study selection process was carried out separately by 
two reviewers to reduce the possibility of rejecting rele-
vant articles. Reviewers used the following blinded and 
structured hierarchical strategy: first, reading titles 
and abstracts; second, reading the articles selected in the 
first phase in full; third, selecting articles fulfilling the spe-
cific inclusion criteria. If any discrepancies arose, a third 
reviewer verified the selection criteria and a consensus was 
reached.
Data extraction
Data were extracted independently by the same research-
ers who selected the studies, who received previous train-
ing for this purpose. Any disagreements were solved by con-
sensus with the help of a third reviewer. The following 
information was extracted from each of the SRs considered: 
databases consulted, use of a manual search or not, time 
period reviewed, study inclusion criteria, number of studies 
and sample size, main objective of the SR, and main con-
clusions of the SR.
Quality assessment
Each article was critically assessed according to its meth-
odological quality. To select articles of scientific value 
meeting the pre-specified inclusion and exclusion criteria 
and reduce bias, SRs had to exceed at least 50% of the max-
imum score of the scale (Oxman ≥ 5). Two reviewers inde-
pendently assessed included studies using the Oxman Scale 
(Oxman, Cook, & Guyatt, 1994). In this scale, scores range 
from 0 to 10 points; higher scores indicate a better quality. 
The scale assesses five areas: i) definition of the subject of 
study of the review (2 points); ii) selection of review arti-
cles (2 points); iii) importance and relevance of articles re-
viewed (2 points); iv) assessment of the quality of studies 
reviewed (2 points); and v) combined results of studies re-
viewed (2 points). 
Any doubts or disagreements between both reviewers 
were resolved by verifying the protocol criteria and subse-
quently reaching consensus.
Results
Identified studies
Using the search strategy described above, we identified a 
total of 21,446 references. After eliminating duplicates, we 
retained 13,367 references. Of these references found as 
of February 2012, 103 were selected by title and abstract. 
The search and selection process used to identify referenc-
es is shown in Figure 1.
Given the large number of SRs identified, we decided to 
limit the review period to cover SRs published since the 
year 2000, assuming that they would include relevant infor-
mation from previous years.
Included and excluded studies
Of the 60 SRs selected and read in full, the following 16 
were included: Barowsky & Schwartz, 2006; Bauer, 
Tharmanathan, Volz, Moeller, & Freemantle, 2009; Ber-
lim & Turecki, 2007; Bschor & Baethge, 2010; Bschor & 
Bauer, 2006; Daban, Martinez-Aran, Cruz, & Vieta, 2008; 
21446 references
identified
13367 references
without duplicates
60 selected
full reading
16 SRs
included
44 SRs
excluded
103 Systematic reviews
references selected
by title and abstract
43 excluded
they were not SRs
13120
references
excluded
Figure 1 Study search and identification.
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Dodd, Horgan, Malhi, & Berk, 2005; Fekadu et al., 2009; 
Lam, Chan, Wilkins-Ho, & Yatham, 2008; Lam, Wan, Co-
hen, & Kennedy, 2002; McPherson et al., 2005; Ruhé, 
van Rooijen, Spijker, Peeters, & Schene, 2012; Sarnecki 
& Temel, 2011; Stimpson, Agrawal, & Lewis, 2002; Tho-
mas, Nandhra, & Jayaraman, 2010; and Trivedi, Nieuws-
ma, & Williams, 2011.
We excluded 44 references from this review because they 
were not systematic reviews or did not meet some of the 
other inclusion criteria described in the protocol.
Methodological quality
Table 1 shows the methodological quality scores of the sys-
tematic reviews included according to the Oxman Scale 
(Oxman, Cook, & Guyatt, 1994).
Characteristics of included studies
Based on the data extraction sheet, we developed Table 2, 
identifying the main characteristics of the studies, and Ta-
ble 3, showing the main objective of the systematic reviews 
included.
Of the 16 SRs included, 13 understood TRD as failure to 
respond to an antidepressant treatment, one included a 
partial response to such treatment (Lam et al., 2008) and 
6 understood TRD as failure to respond to one or more 
ADs (Berlim & Turecki, 2007; Bschor & Bauer, 2006; 
Fekadu et al., 2009, Lam et al., 2002; McPherson et al., 
2005; Thomas et al., 2010). Two SRs (Barowsky & 
Schwartz, 2006; Sarnecki & Temel, 2011) considered 
Thase and Rush stages (1997) and one SR dealt with TRD 
staging methods. Table 2 identifies the characteristics of 
the studies and Table 3 shows the main objective of the 
SRs included.
The main findings obtained for each SR are shown in Ta-
ble 4, clustered into eight different themes.
Definition of treatment-resistant depression  
and staging methods
Overall, results of randomized controlled trials (RCTs) differed 
in most of the conceptual and methodological issues related 
to TRD. Among five staging methods found in the literature, 
the Thase and Rush method was the most widely used.
Long-term results
Although TRD is associated with worse clinical course and 
clinical and social consequences, its long-term evolution is 
based on a heterogeneous group of studies of limited meth-
odological quality.
Venlafaxine
Studies provide evidence of the clinical efficacy of this drug 
in achieving therapeutic response and remission of symp-
toms. Venlafaxine appears to be more effective than selec-
tive serotonin reuptake inhibitors (SSRIs) and at least as ef-
fective as tricyclic ADs.
Switching ADs
There is a discrepancy between published evidence and the 
decision to switch ADs frequently in clinical practice.
Combining ADs
Combining ADs with different mechanisms of action is a 
strategy that seems effective. In fact, some success has 
Table 1 Quality level of SRs included according to the Oxman Scale.
Author Oxman 1 Oxman 2 Oxman 3  Oxman 4  Oxman 5 Oxman
 Subject Selection  Importance  Quality of Combined Total /10) 
  (/2) (/2) and relevance studies (/2) results (/2)  
   (/2)   
Barowsky & Schwartz (2006) 2 2 1 2 0 7
Bauer et al. (2009) 2 2 2 0 2 8
Berlim & Turecki (2007) 2 2 2 1 0 7
Bschor & Bauer (2006) 2 2 1 0 1 7
Bschor & Baethge (2010) 2 2 2 0 1 7
Daban et al. (2008) 2 2 1 0 0 5
Dodd et al. (2005) 2 2 2 1 0 7
Fekadu et al. (2009) 2 2 2 0 0 7
Lam et al. (2008) 2 2 2 2 1 9
Lam et al. (2002) 2 2 1 0 0 5
McPherson et al. (2005) 2 2 2 2 0 8
Ruhé et al. (2012) 2 2 2 2 0 8
Stimpson et al. (2002) 2 2 2 2 0 8
Sarnecki & Temel (2011) 2 2 1 1 0 6
Thomas et al. (2010) 2 1 1 1 0 5
Trivedi et al. (2011) 2 2 2 2 0 8
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been observed with combinations of bupropion plus an SSRI, 
reboxetine plus an SSRI, venlafaxine plus mirtazapine, and 
a monoaminoxidase inhibitor plus a tricyclic AD.
Augmenting antidepressant drugs
Adding lithium is recommended as a treatment strategy for 
patients who do not respond adequately to standard treat-
ment with ADs in international guidelines and reviews. 
However, there is little evidence of the use of other com-
pounds such as lamotrigine.
Psychological treatments
Although such treatments are commonly used and often 
recommended after medication has failed, there is little 
evidence of their effectiveness.
Somatic treatments
Overall, specific parameters of stimulation and side effects 
are yet to be defined for rTMS and vagus nerve stimulation, 
the most beneficial deep brain stimulation techniques.
Table 2 Characteristics of SRs included. 
Author Data base Manual search Years Criteria Nº Studies (Nº Subjects)
Barowsky &  Medline Not conducted 1989-2005 All types of Not reported 
Schwartz (2006)    studies  (Not specified)
Bauer et al. (2009) Medline, Embase,  Unpublished Up to 2007 RCTs 63 trials 
 Cochrane trials    
Berlim & Turecki  Medline, Cochrane,  Reference January 1996 –  RCTs on 47 trials 
(2007) Embase, PsycInfo section June 2006 stimulation  
    techniques 
Bschor & Bauer Medline Reference section 1980 – Dec.  Lithium 28 prospective studies 
(2006)   2003   (838)
Bschor & Baethge Medline, Embase,  Reference section Not specified Not responding 3 RCTs (1111)  
(2010) Central    to ADs  
Daban et al. (2008) Medline, Current  Not specified Jan. 2000 –  Patients 18 (1085) 
 Contents, Embase,   Sep. 2007 implanted with  
 Psychological    VNS  
 Abstracts    
Dodd et al. (2005) Psychlit Reference section Up to Jan. 2005 RCTs 24 trials
Fekadu et al. (2009) Medline, Embase,  Reference 1960 – Jun.  ≥ 6 months 9 observational (1279) 
 PsycInfo section  2008  follow-up 
Lam et al. (2002) Medline Reference section 1986 –  Any 27 studies (6670) 
   Jun. 2001 combination  
    of 2 ADs 
Lam et al. (2008) CCTR, Embase,  Reference 1966 –  RCTs on rTMS 24 (1092) 
 Medline, PsycInfo section 15 May 2008  
McPherson et al.  CRD Reference 1988 –  All designs 12 
(2005)  section 2001 and languages  
Ruhé et al. (2012) Embase, PsycInfo,  Reference 1985 –  Articles defining 11 
 Pubmed section January 2010 staging models  
Sarnecki & Temel  CCTR, Embase,  Contacting 1966 –  RCTs on 17 (645) 
(2011) Lilacs, Medline,  authors Jan. 2001 treatments  
 Psychlit, PsycInfo     
Stimpson et al. Medline Not conducted Before March  RCTs  
(2002)   2010  6 studies (50)
Thomas et al. (2010) CCDANCTR, CCTR,  Reference section Medline:  RCTs on 10 (23) 
 Central, Cinahl,   1966+  lamotrigine  
 Embase, Medline/   Embase:    
 Pubmed, PsycInfo  1980+ Cinahl:  
   1982+ PsycInfo:  
   1974+  
Trivedi et al. (2011) CCTR, Embase,  Reference section Up to RCTs 13 (592) 
 PsycInfo, PubMed  07/09/2010  
Note. AD = Antidepressant; CCTR = Cochrane Central Register of Controlled Trials; CCDANCTR = Cochrane Collaboration Depression, 
Anxiety and Neurosis Controlled Trials Register; CRD = Centre for Reviews and Dissemination; TRD = Treatment-Resistant Depression; 
VNS = Vagus Nerve Stimulation; rTMS = repetitive Transcranial Magnetic Stimulation; SSRI = Selective Serotonine Reuptake Inhibitor; 
RCTs = Randomized Control Trials.
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Discussion and conclusions
There are currently many treatment options available once 
an AD trial has failed (Ruelaz, 2006), such as switching to 
another AD (Barowsky & Schwartz, 2006; Bschor & Bauer, 
2006), combining two ADs of the same or a different class 
(Dodd et al., 2005; Lam et al., 2002), or augmenting the AD 
with other pharmacological substances (Gabriel, 2006; 
Nierenberg et al., 2003; Rocha & Hara, 2003). However, the 
present SR revealed that the literature available to date 
does not show consistent results for any of these strategies. 
We found a discrepancy between published evidence and 
the frequent decision to switch, combine, or augment anti-
depressants in clinical practice. 
With regard to somatic treatments, only a moderate per-
centage of patients were found to gain relief with deep brain 
stimulation techniques, but results should not be generalized 
as sample sizes are small and a robust research methodology 
is needed (Kennedy & Giacobbe, 2007). Repetitive transcra-
nial magnetic stimulation (rTMS) appears to provide signifi-
cant benefits in short-term treatment studies. Yet, the rela-
tively low response and remission rates, short durations of 
treatment, and relative lack of systematic follow-up studies 
suggest that further studies are needed before rTMS can be 
considered as a first-line monotherapy treatment for TRD 
(Bretlau et al., 2010; Triggs et al., 2010). Vagus nerve stimu-
lation seems to be an interesting new approach to treat TRD, 
but results are reported mainly in open studies. Therefore, 
further clinical trials are needed to confirm its efficacy in 
major depression. Overall, it has not been possible to deter-
mine the most beneficial stimulation areas, parameters, and 
side effects for these three somatic treatments yet.
Table 3 Main objective of SRs included.
Author Objective Main theme
Barowsky & Schwartz To establish state of the matter regarding augmentation  Augmentation and 
(2006) and combining strategies with lithium, thyroid hormone  combination 
 and other compounds, for TRD 
Bauer et al. (2009) Meta-analysis of trials of Venlafaxine in the treatment  Venlafaxine 
 of MDD, including treatment resistant depression and long   
 term relapse prevention 
Berlim & Turecki (2007) To summarize and discuss the conceptual and operational  TRD definition 
 definitions of TRD by systematically reviewing RCTs  
 on its somatic treatments 
Bschor & Bauer (2006) It reviews the clinical evidence and hypotheses on the mode  Augmentation with Lithium 
 of action of lithium augmentation 
Bschor & Baethge To summarise the scientific findings on switching antidepressants  Swtching ADs 
(2010) to manage TRD patients 
Daban et al. (2008) To evaluate the safety and efficacy of VNS in TRD VNS
Dodd et al. (2005) To review published trials on combination antidepressants with a  Combining ADs 
 view to inform clinical practice 
Fekadu et al. (2009) To assess how people with TRD fare in the longer term, from  Long-term outcomes 
 information gathered in observational studies. We were not interested  for TRD patients 
 in acute treatment trials of TRD, but in studies which provided data  
 on the longer term outcome of those who either had ongoing  
 depressive symptoms after treatment or who had previously  
 experienced TRD but responded successfully to treatment 
Lam et al. (2008) To find clear evidence of rTMS for TRD focusing on clinical outcomes  rTMS 
 that are relevant to clinicians 
Lam et al. (2002) To critically evaluate the evidence for efficacy of combining  Combining ADs 
 antidepressants 
McPherson et al. (2005) To evaluate psychological interventions with treatment resistant Psychological treatments 
 depression 
Ruhé et al. (2012) To identify staging models for TRD and compare them regarding  Staging methods 
 predictive utility and reliability 
Stimpson et al. (2002) To give a summation of the findings of the clinical studies on DBS  Deep Brain Stimulation 
 and TRD that have been concluded thus far 
Sarnecki & Temel (2011) To summarise the findings from all RCTs that have assessed the  Pharmacological and 
 efficacy of a pharmacological or psychological intervention for TRD psychological interventions
Thomas et al. (2010) To review all the evidence of lamotrigine’s effectiveness in treatment  Augmentation with 
 resistant depression after at least one failed antidepressant trial Lamotrigine
Trivedi et al. (2011) To examine the utility of psychotherapy in managing treatment  Psychotherapy 
 resistant depression 
Note. AD = Antidepressant; TRD = Treatment-Resistant Depression; MDD = Major Depressive Disorder; VNS = Vagus Nerve Stimulation; 
rTMS = repetitive Transcranial Magnetic Stimulation; RCTs = Randomized Control Trials.
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Table 4 Main findings of individual SRs included.
Study Main findings
Barowsky &  The idea that the most common augmentation strategies in depression are those with the least controlled  
Schwartz  evidence highlights the fact that much of psychopharmacology is also an “art” in which clinicians prescribe 
(2006) based on anecdotal experience of positive patient responses based on particular depressive symptoms
Bauer et al. Venlafaxine appears superior to SSRIs for both response and remission, with similar overall tolerability, derived  
(2009) from a lower rate of drop out for inefficacy and a higher rate of drop out from side effects
Berlim & Overall, RCTs diverged regarding the majority of the conceptual and methodological issues involved in the  
Turecki ascertainment of TRD, this is: 1) number and type of previous failed trials needed to establish a diagnosis of TRD,  
(2007) definition of treatment adequacy (dose, titration, and duration), the definition of treatment response, and the  
 assessment of primary and comorbid diagnoses
Bschor &  Lithium augmentation is recommended as a first-line treatment strategy for patients with a major depressive 
Bauer episode who did not adequately respond to standard antidepressant treatment in international guidelines  
 and (2006) reviews. Is the response to lithium augmentation a “true” augmentation effect, resulting from  
 a specific pharmacological interaction between lithium and the antidepressant, or is it simply the antidepressant 
 effect of lithium alone?
Bschor   There is a discrepancy between the published evidence and the frequent decision to switch antidepressants, 
& Baethge  indicating an urgent need for more controlled studies. Pending such studies they recommend that physicians rely 
(2010) on more thoroughly evaluated strategies
Daban et al.  VNS seems to be an interesting new approach to treating TRD. However, despite the promising results reported  
(2008) mainly in open studies, further clinical trials are needed to confirm its efficacy in major depression
Dodd et al.  Data suggests that combining antidepressants with different mechanisms of action is a worthwhile strategy with  
(2005) some observed success with combinations of bupropion plus an SSRI, reboxetine plus an SSRI, mirtazapine plus  
 venlafaxine, and a MAOI plus a TCA
Fekadu et al.  TRD is associated with poorer clinical outcome, particularly among those who require multiple antidepressant  
(2009) medications. The main limitations of the review arise from the variability in recruitment procedures, definitions  
 and outcome assessments of the original studies
Lam et al. For patients with TRD, rTMS appears to provide significant benefits in short-term treatment studies. However, the 
(2008)  relatively low response and remission rates, the short durations of treatment, and the relative lack of systematic 
  follow-up studies suggest that further studies are needed before rTMS can be considered as a first-line  
 monotherapy treatment for TRD
Lam et al.  Given the high rates of inadequate response to current treatments, it is important to better evaluate the efficacy 
(2002) of combination antidepressant treatment. Future RCTs should incorporate study designs that are more likely  
 to determine efficacy vs. monotherapy with the second drug
McPherson Psychological treatments for depression are commonly delivered and often recommended following the failure of  
et al. (2005) medication. The paucity of evidence for their effectiveness in these situations is a significant problem. There is a 
 need for studies with a strong controlled design investigating the effectiveness of psychological treatments for  
 patients with treatment-resistant depression
Ruhé et al. Despite validation of the MSM, further investigation of the reliability and predictive utility of TRD staging models  
(2012) and additional disease characteristics is required. Correct staging of TRD might improve generalizability of results 
 from clinical studies and improve delivery of care to TRD patients. They propose methods to validate staging  
 models in TRD
Sarnecki &  Treatment-refractory depression is common in clinical practice but there is little evidence to inform  
Temel (2011) management. There was some evidence of benefit for lithium augmentation, but the evidence was very weak.  
 In the absence of good evidence, clinicians will have to rely upon their own clinical judgement in deciding upon  
 treatment
Stimpson Only a moderate percentage of patients gained relief. However, sample sizes were small and a lack of proper  
et al. (2002) research methodology was apparent; as a consequence, the most beneficial stimulation areas, parameters and its 
  side-effects are not yet determinable
Thomas et al. There is little evidence to guide the use of lamotrigine for depression that has not responded to a course of  
(2010) antidepressants
Trivedi et al.  There is a pressing need to examine psychotherapy as a second step treatment in patients who have not  
(2011) responded to initial antidepressants treatment. This may be addressed in two ways: 1) re-analysis of  
 existing data from trials in which patients with treatment resistant depression are recruited, or  
 2) conducting studies designed to examine this question. As a field, it is important to develop a  
 standardized, operational definition of treatment resistant depression to facilitate comparisons across  
 studies
Note. TRD = Treatment-Resistant Depression; VNS = Vagus Nerve Stimulation; SSRI = Selective Serotonine Reuptake Inhibitor; MAOI = 
Monoamine Oxidase Inhibitors; MSM = Maudsley Staging Method; TCA = Tricyclic Antidepressants; VNS =: Vagus Nerve Stimulation; rTMS = 
Transcranial Magnetic Stimulation; RCTs = Randomized Control Trials.
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Data about psychological treatments for depression show 
that they are commonly delivered and recommended follow-
ing the failure of medication, but the scarce evidence of 
their effectiveness in these situations is a significant prob-
lem (Anderson, Nutt, & Deakin, 2000; Parker, Blanch, & 
Crawford, 2010). There is a need for studies with a strong 
controlled design exploring the effectiveness of psychologi-
cal treatments for patients with TRD and assessing psycho-
therapy as a second step treatment in patients not respond-
ing to initial treatment with antidepressants. It is also 
important to develop a standardized, operational definition 
of TRD to facilitate comparisons across studies (McPherson et 
al., 2005).
Although it was not the main aim of this research, this 
systematic review revealed, in line with many research 
studies (e.g., Bschor & Bauer, 2006; Catafau et al., 2001; 
Kennedy & Giacobbe, 2007; O’Reardon, Thase, & Papakos-
tas, 2009), a considerable heterogeneity regarding most 
conceptual and methodological issues involved in the ascer-
tainment of TRD in the published literature. More specifi-
cally, there are major differences in the number and type 
of previous failed trials required to make a diagnosis of 
TRD, the definition of treatment adequacy (dose, titration, 
and duration) and treatment response, and the assessment 
of primary and comorbid diagnoses. As regards the five 
staging methods found by our SR in the literature, the 
Thase and Rush method (1997) and the Maudsley Staging 
Method (Fekadu et al., 2009) were those most widely used. 
However, it is necessary to further explore the reliability 
and predictive utility of TRD staging models and additional 
disease characteristics. In this regard, the NICE (2009) pro-
poses understanding TRD from a dimensional perspective 
for patients who show an inadequate response to treat-
ment. This approach starts with the least intrusive inter-
vention and patients who do not show any response are of-
fered a sequenced structured intervention in several 
consecutive steps. It should be noted that patients who 
show a poor response to treatment are also considered in 
this new conceptualization. 
It is important to note that conclusions are limited to the 
information and methodological quality of the available 
scientific evidence included in this SR. In addition, the au-
thors consider that the articles published omit information 
of particular interest in the case of TRD that might be rele-
vant to the interpretation of results (e.g., comorbidity with 
other disorders or physical or mental illness). In this regard, 
some of the first articles selected were excluded because 
they did not include a definition of TRD. In this research, 
TRD was understood as failure to respond to one or more AD 
treatments. Therefore, conclusions are to be reached only 
within this context.
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